Akin to the findings above, the combination treatment of ABT263 and GW3965 reduced tumor growth significantly stronger than each compound on its own (Fig 7E and F, and Appendix Fig S10C), suggesting that overall our treatment concept of inhibition of Bcl‐2 family members along with activation of LXR agonists is a viable approach for a range of solid tumors. Here, BCL2 is linked to neoplasm.